Literature DB >> 24493818

Lymphatic specific disruption in the fine structure of heparan sulfate inhibits dendritic cell traffic and functional T cell responses in the lymph node.

Xin Yin1, Scott C Johns, Daniel Kim, Zbigniew Mikulski, Catherina L Salanga, Tracy M Handel, Mónica Macal, Elina I Zúñiga, Mark M Fuster.   

Abstract

Dendritic cells (DCs) are potent APCs essential for initiating adaptive immunity. Following pathogen exposure, trafficking of DCs to lymph nodes (LNs) through afferent lymphatic vessels constitutes a crucial step in the execution of their functions. The mechanisms regulating this process are poorly understood, although the involvement of certain chemokines in this process has recently been reported. In this study, we demonstrate that genetically altering the fine structure (N-sulfation) of heparan sulfate (HS) specifically in mouse lymphatic endothelium significantly reduces DC trafficking to regional LNs in vivo. Moreover, this alteration had the unique functional consequence of reducing CD8(+) T cell proliferative responses in draining LNs in an ovalbumin immunization model. Mechanistic studies suggested that lymphatic endothelial HS regulates multiple steps during DC trafficking, including optimal presentation of chemokines on the surface of DCs, thus acting as a co-receptor that may function "in trans" to mediate chemokine receptor binding. This study not only identifies novel glycan-mediated mechanisms that regulate lymphatic DC trafficking, but it also validates the fine structure of lymphatic vascular-specific HS as a novel molecular target for strategies aiming to modulate DC behavior and/or alter pathologic T cell responses in lymph nodes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24493818      PMCID: PMC3960083          DOI: 10.4049/jimmunol.1301286

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

Review 1.  Lymph node homing of T cells and dendritic cells via afferent lymphatics.

Authors:  Reinhold Förster; Asolina Braun; Tim Worbs
Journal:  Trends Immunol       Date:  2012-03-27       Impact factor: 16.687

2.  Endothelial heparan sulfate controls chemokine presentation in recruitment of lymphocytes and dendritic cells to lymph nodes.

Authors:  Xingfeng Bao; E Ashley Moseman; Hideo Saito; Bronislawa Petryniak; Bronislawa Petryanik; Aude Thiriot; Shingo Hatakeyama; Yuki Ito; Hiroto Kawashima; Yu Yamaguchi; John B Lowe; Ulrich H von Andrian; Minoru Fukuda
Journal:  Immunity       Date:  2010-11-24       Impact factor: 31.745

3.  Chemokine CXCL12 uses CXCR4 and a signaling core formed by bifunctional Akt, extracellular signal-regulated kinase (ERK)1/2, and mammalian target of rapamycin complex 1 (mTORC1) proteins to control chemotaxis and survival simultaneously in mature dendritic cells.

Authors:  Cristina Delgado-Martín; Cristina Escribano; José Luis Pablos; Lorena Riol-Blanco; José Luis Rodríguez-Fernández
Journal:  J Biol Chem       Date:  2011-08-30       Impact factor: 5.157

Review 4.  Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function.

Authors:  C L Salanga; T M Handel
Journal:  Exp Cell Res       Date:  2011-01-09       Impact factor: 3.905

5.  Interstitial dendritic cell guidance by haptotactic chemokine gradients.

Authors:  Michele Weber; Robert Hauschild; Jan Schwarz; Christine Moussion; Ingrid de Vries; Daniel F Legler; Sanjiv A Luther; Tobias Bollenbach; Michael Sixt
Journal:  Science       Date:  2013-01-18       Impact factor: 47.728

6.  Lymphatic endothelial heparan sulfate deficiency results in altered growth responses to vascular endothelial growth factor-C (VEGF-C).

Authors:  Xin Yin; Scott C Johns; Roger Lawrence; Ding Xu; Krisanavane Reddi; Joseph R Bishop; Judith A Varner; Mark M Fuster
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

7.  The chemokine receptor 7 regulates cell adhesion and migration via beta1 integrin in metastatic squamous cell carcinoma of the head and neck.

Authors:  Peng Li; Zhen-Jin Zhao; Fa-Yu Liu; Li-Yan Sun; Xue Ding; Wen-Zhong Zhang; De-Hao Shang; Chang-Fu Sun
Journal:  Oncol Rep       Date:  2010-10       Impact factor: 3.906

8.  CCR7 essentially contributes to the homing of plasmacytoid dendritic cells to lymph nodes under steady-state as well as inflammatory conditions.

Authors:  Sebastian Seth; Linda Oberdörfer; Rebecca Hyde; Kirstin Hoff; Verena Thies; Tim Worbs; Susanne Schmitz; Reinhold Förster
Journal:  J Immunol       Date:  2011-02-04       Impact factor: 5.422

9.  Retro-orbital injections in mice.

Authors:  Tal Yardeni; Michael Eckhaus; H Douglas Morris; Marjan Huizing; Shelley Hoogstraten-Miller
Journal:  Lab Anim (NY)       Date:  2011-05       Impact factor: 12.625

10.  A critical role for lymphatic endothelial heparan sulfate in lymph node metastasis.

Authors:  Xin Yin; Jadwiga Truty; Roger Lawrence; Scott C Johns; R Sathish Srinivasan; Tracy M Handel; Mark M Fuster
Journal:  Mol Cancer       Date:  2010-12-20       Impact factor: 27.401

View more
  9 in total

1.  Genetic Mechanisms of Immune Evasion in Colorectal Cancer.

Authors:  Catherine S Grasso; Marios Giannakis; Daniel K Wells; Tsuyoshi Hamada; Xinmeng Jasmine Mu; Michael Quist; Jonathan A Nowak; Reiko Nishihara; Zhi Rong Qian; Kentaro Inamura; Teppei Morikawa; Katsuhiko Nosho; Gabriel Abril-Rodriguez; Charles Connolly; Helena Escuin-Ordinas; Milan S Geybels; William M Grady; Li Hsu; Siwen Hu-Lieskovan; Jeroen R Huyghe; Yeon Joo Kim; Paige Krystofinski; Mark D M Leiserson; Dennis J Montoya; Brian B Nadel; Matteo Pellegrini; Colin C Pritchard; Cristina Puig-Saus; Elleanor H Quist; Ben J Raphael; Stephen J Salipante; Daniel Sanghoon Shin; Eve Shinbrot; Brian Shirts; Sachet Shukla; Janet L Stanford; Wei Sun; Jennifer Tsoi; Alexander Upfill-Brown; David A Wheeler; Catherine J Wu; Ming Yu; Syed H Zaidi; Jesse M Zaretsky; Stacey B Gabriel; Eric S Lander; Levi A Garraway; Thomas J Hudson; Charles S Fuchs; Antoni Ribas; Shuji Ogino; Ulrike Peters
Journal:  Cancer Discov       Date:  2018-03-06       Impact factor: 39.397

2.  E2F-1 promotes DAPK2-induced anti-tumor immunity of gastric cancer cells by targeting miR-34a.

Authors:  Lin-Hai Yan; Zhi-Ning Chen; Li Li; Jia Chen; Xian-Wei Mo; Yu-Zhou Qin; Wen-E Wei; Hai-Quan Qin; Yuan Lin; Jian-Si Chen
Journal:  Tumour Biol       Date:  2016-10-04

3.  Lymphatic Regulation of Cellular Trafficking.

Authors:  David G Jackson
Journal:  J Clin Cell Immunol       Date:  2014-10-01

Review 4.  Dendritic cell-based vaccine efficacy: aiming for hot spots.

Authors:  Gabriela Andrea Pizzurro; María Marcela Barrio
Journal:  Front Immunol       Date:  2015-03-03       Impact factor: 7.561

5.  Increased migration of antigen presenting cells to newly-formed lymphatic vessels in transplanted kidneys by glycol-split heparin.

Authors:  Ditmer T Talsma; Kirankumar Katta; Miriam Boersema; Saritha Adepu; Annamaria Naggi; Giangiacomo Torri; Coen Stegeman; Gerjan Navis; Harry van Goor; Jan-Luuk Hillebrands; Saleh Yazdani; Jacob van den Born
Journal:  PLoS One       Date:  2017-06-30       Impact factor: 3.240

Review 6.  Leucocyte Trafficking via the Lymphatic Vasculature- Mechanisms and Consequences.

Authors:  David G Jackson
Journal:  Front Immunol       Date:  2019-03-14       Impact factor: 7.561

Review 7.  ADAMTS proteases and the tumor immune microenvironment: Lessons from substrates and pathologies.

Authors:  Silvia Redondo-García; Carlos Peris-Torres; Rita Caracuel-Peramos; Juan Carlos Rodríguez-Manzaneque
Journal:  Matrix Biol Plus       Date:  2020-12-30

8.  Shape and Function of Interstitial Chemokine CCL21 Gradients Are Independent of Heparan Sulfates Produced by Lymphatic Endothelium.

Authors:  Kari Vaahtomeri; Christine Moussion; Robert Hauschild; Michael Sixt
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

9.  Functional Cellular Anti-Tumor Mechanisms are Augmented by Genetic Proteoglycan Targeting.

Authors:  Purva Gupta; Scott C Johns; So Young Kim; Roland El Ghazal; Elina I Zuniga; Mark M Fuster
Journal:  Neoplasia       Date:  2019-12-30       Impact factor: 5.715

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.